Humana
HUM
$306.00
+0.29%
Humana Inc. is one of the largest private health insurers in the United States, operating primarily in the Medical - Healthcare Plans industry. The company has built a distinct niche by specializing in government-sponsored programs, with nearly all its medical membership derived from Medicare, Medicaid, and the military's Tricare program, and it also provides other healthcare services like primary care and pharmacy benefit management through its CenterWell segment. The current investor narrative is dominated by the impact of regulatory changes on Medicare Advantage payments, as evidenced by recent news highlighting a sector-wide jump following a favorable 2027 payment update from CMS, which has improved revenue visibility and sentiment. However, the stock has experienced significant volatility, reflecting ongoing debates about the sustainability of its profit margins and growth trajectory within the government-sponsored healthcare landscape.…
HUM
Humana
$306.00
Related headlines
Investment Opinion: Should I buy HUM Today?
Rating: Hold. The core thesis is that Humana presents a high-risk, high-potential-reward situation where the extreme valuation discount is counterbalanced by severe and unresolved fundamental deterioration, warranting caution until profitability stabilizes.
Supporting evidence for this neutral stance includes the stock's deep value metrics (PS of 0.24, EV/Sales of 0.21), which are far below sector averages, creating a margin of safety. However, this is offset by the catastrophic Q4 fundamentals: a -$796 million net loss, an 11.67% gross margin, and -$1.85 billion in free cash flow. The forward P/E of 19.9 prices in a robust earnings recovery to an estimated $41.26 EPS, but the wide analyst estimate range and prevalence of Hold ratings reflect justified skepticism. The powerful +65.74% 3-month technical rebound suggests the worst may be priced in, but it does not confirm a fundamental turnaround.
The two biggest risks that could invalidate a future Buy thesis are: 1) Medical cost trends failing to improve, leading to another significant earnings miss, and 2) A reversal of the recent positive regulatory sentiment. This Hold would upgrade to a Buy if the company demonstrates a return to consistent quarterly profitability (e.g., net income margin above 2%) and positive operating cash flow, confirming the margin recovery story. It would downgrade to a Sell if revenue growth decelerates sharply below 5% or if the Q4 cash burn proves not to be an anomaly. Currently, the stock is fairly valued relative to its broken near-term fundamentals but deeply undervalued relative to its historical earnings power—a classic 'show me' story.
Sign up to view all
HUM 12-Month Price Forecast
Humana is in a precarious transitional phase. The powerful technical rebound and regulatory reprieve have likely put a floor under the stock, but the path to a sustained recovery is fraught with risk given the severity of the recent profitability collapse. The base case of a volatile, range-bound recovery is most probable, as the company will need several quarters to prove its margin recovery is real. The stance is neutral due to the high degree of binary outcomes; evidence of sustained positive cash flow and net income would be required to become bullish, while another quarter of massive losses would quickly validate the bear case. Investors are essentially underwriting a turnaround story at a discounted price.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $397.80 and implied upside of +30.0% versus the current price.
Average Target
$397.80
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$245 - $398
Analyst target range
Analyst coverage is moderate with 13 firms providing estimates, and the recent institutional rating actions show a cautious to neutral stance, with several firms (Barclays, Wells Fargo, Truist, TD Cowen, UBS, Cantor Fitzgerald) maintaining Hold/Equal Weight/Neutral ratings in February 2026, while Goldman Sachs has a Sell and Jefferies and Guggenheim maintain Buy ratings. The consensus recommendation based on this distribution leans neutral, reflecting high uncertainty following the stock's crash and partial recovery, with analysts awaiting clearer signs of fundamental stabilization. The average revenue estimate for the coming period is $207.23 billion, with a range from $200.10 billion to $217.77 billion, and the average EPS estimate is $41.26, ranging from $39.42 to $44.00, but a specific consensus price target is not provided in the data to calculate implied upside. The wide range in both revenue and EPS estimates signals high uncertainty among analysts regarding the company's near-term financial performance, particularly around medical cost trends and the impact of Medicare rate changes. The lack of a unified price target and the prevalence of Hold ratings indicate that while the severe valuation discount is acknowledged, analysts require more evidence of a sustained turnaround before adopting a more bullish stance, leaving the stock in a 'show me' story phase where fundamentals must improve to drive the next leg of the recovery.
Bulls vs Bears: HUM Investment Factors
The investment debate for Humana is a classic battle between deep value and broken fundamentals. The bull case, currently supported by stronger recent momentum, hinges on the extreme valuation discount (PS of 0.24) and a powerful technical reversal fueled by a positive regulatory catalyst. The bear case is grounded in the severe and recent collapse of profitability and cash flow, which raises existential questions about the business model's sustainability. The single most important tension is whether the company can translate its solid 11.3% revenue growth and the favorable CMS payment update into a credible and sustained recovery of its profit margins. If margins stabilize near historical levels, the stock's deep discount offers substantial upside. If the Q4 loss proves indicative of a new, lower-margin reality, the current valuation may be justified or even too high.
Bullish
- Extreme Valuation Discount: Humana trades at a trailing PS ratio of 0.24 and EV/Sales of 0.21, a severe discount to the typical healthcare plans sector which often trades above 0.5x sales. This deep discount prices in a worst-case scenario and offers significant potential upside if profitability recovers.
- Powerful Technical Rebound: The stock has surged +53.81% in the past month and +65.74% over three months, decisively reversing its prior collapse. This explosive momentum, coupled with a high short ratio of 3.25, suggests a fundamental shift in sentiment, likely driven by short covering and positive regulatory news.
- Regulatory Tailwind from CMS: Recent news highlights a favorable 2027 Medicare Advantage payment update from CMS, which has boosted revenue visibility and sentiment across the sector. This regulatory reprieve directly addresses a key overhang and improves the long-term profit outlook for Humana's core business.
- Strong Top-Line Growth: Q4 2025 revenue grew 11.3% year-over-year to $32.52 billion, demonstrating robust demand for its government-sponsored insurance plans. This consistent top-line expansion provides a solid foundation for earnings recovery if margin pressures abate.
Bearish
- Severe Profitability Collapse: Q4 2025 reported a net loss of -$796 million, a gross margin of only 11.67%, and a negative operating margin of -3.15%. This sharp deterioration from Q1's net income of $1.244 billion and 17.37% gross margin indicates deep-seated operational and medical cost challenges.
- Catastrophic Cash Burn: In Q4 2025, operating cash flow was -$1.652 billion and free cash flow was -$1.854 billion. While TTM FCF remains positive at $375 million, this quarterly cash burn raises serious concerns about the company's ability to internally fund operations if losses persist.
- Extreme Earnings Volatility: The company's earnings have swung wildly, from a $1.244 billion profit in Q1 2025 to a -$796 million loss in Q4. This extreme quarterly volatility, with a -47.54% max drawdown, demonstrates high idiosyncratic risk and makes the stock difficult to value reliably.
- Analyst Uncertainty & Neutral Stance: Analyst consensus leans neutral, with several firms maintaining Hold ratings. The wide EPS estimate range of $39.42 to $44.00 signals high uncertainty, and the lack of a unified price target indicates a 'show me' story where fundamentals must improve to drive conviction.
HUM Technical Analysis
The stock is in a powerful recovery trend following a severe drawdown, with the 1-year price change of +34.14% masking the extreme volatility experienced. As of the latest close at $305.12, the price is trading at approximately 80% of its 52-week range ($163.11 to $315.35), indicating it has recovered substantially from its lows but remains below its recent peak, suggesting room for further recovery if momentum holds. The short-term momentum is exceptionally strong and diverges positively from the longer-term trend, with a 1-month surge of +53.81% and a 3-month gain of +65.74%, far outpacing the S&P 500's respective returns of +5.6% and +8.42%, signaling a decisive bullish reversal from the January-February collapse. This explosive rebound, coupled with a high short ratio of 3.25, suggests the move may have been fueled by short covering and a dramatic shift in sector sentiment following positive regulatory news. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $315.35 and major support at the 52-week low of $163.11; a breakout above resistance would confirm a full recovery and potentially open the path to new highs, while a failure could see the stock retest the $250-$275 consolidation zone. The stock's beta of 0.683 indicates it has been less volatile than the broader market over the measured period, but the massive -47.54% max drawdown and recent parabolic move demonstrate it can exhibit extreme idiosyncratic risk, particularly around earnings and regulatory announcements.
Beta
0.68
0.68x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$315
Price range past year
Annual Return
+28.6%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | +49.2% | +4.0% |
| 3m | +65.4% | +8.2% |
| 6m | +33.7% | +11.5% |
| 1y | +28.6% | +24.3% |
| ytd | +15.7% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Revenue growth remains robust but is overshadowed by severe profitability issues, with Q4 2025 revenue of $32.52 billion representing an 11.3% year-over-year increase, continuing a trend of solid top-line expansion driven by its government-focused insurance business. However, the growth trajectory is marred by extreme quarterly volatility in earnings, as the Insurance Segment contributed $31.34 billion in revenue while the CenterWell Segment added $5.96 billion, but the overall business model is currently under significant pressure. Profitability has completely collapsed in the most recent quarter, with Q4 2025 reporting a net loss of -$796 million and a gross margin of only 11.67%, a sharp deterioration from the Q1 2025 net income of $1.244 billion and gross margin of 17.37%, indicating severe margin compression and potential underpricing in its core Medicare Advantage plans. The operating margin turned deeply negative at -3.15% in Q4, compared to a positive 5.13% in Q1, highlighting the operational challenges and the impact of higher medical costs that have plagued the managed care sector. The balance sheet and cash flow position reveal significant stress, with Q4 2025 operating cash flow deeply negative at -$1.652 billion and free cash flow at -$1.854 billion, though the trailing twelve-month free cash flow remains positive at $375 million. The debt-to-equity ratio of 0.73 is manageable, and the current ratio of 0.72 indicates adequate, though not robust, short-term liquidity, but the dramatic cash burn in the latest quarter raises concerns about the company's ability to internally fund operations if the profitability downturn persists.
Quarterly Revenue
$32.5B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.11%
Latest Quarter
Free Cash Flow
$375000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Given the company reported a net loss in the most recent quarter, the Price-to-Sales (PS) ratio is the most appropriate primary valuation metric. Humana trades at a trailing PS ratio of 0.24 and an EV/Sales of 0.21, which are extremely low multiples that reflect the market's severe discount due to the recent collapse in profitability. The forward PE ratio of 19.9, based on estimated EPS, suggests the market is pricing in a significant earnings recovery, creating a large gap between the depressed current fundamentals and future expectations. Compared to industry averages, Humana's PS ratio of 0.24 represents a substantial discount to the typical healthcare plans sector, which often trades above 0.5x sales, indicating the market is penalizing it more heavily than peers for its recent earnings miss and margin woes. This deep discount may be justified in the near term given the profit collapse, but it also creates potential upside if the company can demonstrate a credible path to margin stabilization and a return to its historical profitability levels. Historically, Humana's own valuation has compressed dramatically from its multi-year highs; for instance, its PS ratio was above 1.0 as recently as early 2024, and its current level of 0.24 is near the bottom of its multi-year range. Trading near historical valuation lows suggests the stock is pricing in a worst-case scenario, offering a potential value opportunity if the fundamental outlook improves, but it also signals the market believes the company's earnings power has structurally deteriorated.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1073x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and immediate. The company's profitability has collapsed, with Q4 2025 reporting a net loss of -$796 million and gross margin compressing to 11.67% from 17.37% in Q1. This was accompanied by catastrophic cash burn, with Q4 operating cash flow at -$1.652 billion. The debt-to-equity of 0.73 is manageable, but the current ratio of 0.72 indicates tight liquidity. The core risk is that higher medical costs and potential underpricing in Medicare Advantage plans have structurally impaired earnings power, requiring a prolonged and uncertain turnaround.
Market & Competitive Risks center on valuation compression and regulatory dependence. Despite its recent surge, the stock's PS ratio of 0.24 remains at a deep discount to the sector, reflecting the market's harsh penalty for its earnings miss. However, this discount could persist or widen if profitability fails to recover as expected. The company's beta of 0.683 suggests lower market correlation, but its -47.54% max drawdown reveals extreme idiosyncratic risk tied to regulatory announcements and earnings. The business is almost entirely dependent on government reimbursement rates, making it a perpetual hostage to CMS policy decisions, as seen in the recent sector-wide volatility.
Worst-Case Scenario involves a failure to contain medical costs combined with an unfavorable future regulatory environment. This could lead to consecutive quarterly losses, a credit rating downgrade due to sustained cash burn, and a loss of market share to more efficient competitors. In this adverse scenario, the stock could retest its 52-week low of $163.11, representing a downside of approximately -47% from the current price of $305.12. A more realistic bear-case target might align with the lower end of its recent consolidation around $180-$200, implying a -30% to -40% decline.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The inability to recover margins, leading to sustained losses and cash burn as seen in Q4 (-$796M net income, -$1.85B FCF). 2) Regulatory Risk: Dependence on government reimbursement (Medicare/Medicaid) makes profits highly sensitive to CMS policy changes. 3) Operational Risk: Extreme quarterly earnings volatility and potential underpricing of medical plans, indicated by the gross margin collapse from 17.37% to 11.67% in 2025. 4) Sentiment Risk: The stock has shown extreme volatility (beta 0.683 but -47.54% drawdown), meaning it can fall sharply on any negative news.
The 12-month forecast is highly bifurcated, with three plausible scenarios. The Base Case (50% probability) sees a volatile recovery to a range of $275-$315, as the company shows gradual margin improvement. The Bull Case (30% probability), fueled by a successful turnaround, targets $315-$350, implying a breakout to new highs. The Bear Case (20% probability), triggered by failed margin recovery, sees a drop to $180-$240, retesting lower support levels. The most likely outcome is the base case, contingent on Humana demonstrating a credible path to stabilizing its profitability over the next two quarters.
HUM is deeply undervalued based on historical norms and sector comparisons, but this discount is justified by its broken near-term fundamentals. Its Price-to-Sales ratio of 0.24 and EV/Sales of 0.21 are at a severe discount to the healthcare plans sector, which often trades above 0.5x sales. Historically, Humana's own PS ratio was above 1.0 in early 2024. The market is effectively pricing in a worst-case scenario for earnings power. The forward P/E of 19.9 shows the market expects a sharp earnings recovery; if that occurs, the stock is undervalued. If not, it may be fairly valued or even overvalued at current levels.
HUM is a speculative buy, not a core investment. For investors with a high risk tolerance and a long time horizon, the extreme valuation discount (PS of 0.24) offers significant potential upside if the company's profitability recovers as analysts expect (forward P/E of 19.9). However, it comes with substantial risk, as evidenced by the recent -$796 million quarterly loss and -47.54% max drawdown. It could be a good buy for those betting on a successful turnaround in the Medicare Advantage sector, but it is unsuitable for risk-averse investors seeking stability or income.
HUM is primarily suited for a medium- to long-term investment horizon (12-24 months minimum) for investors betting on a fundamental turnaround. The stock's high volatility, lack of a meaningful dividend (yield 1.39%), and current lack of earnings visibility make it a poor candidate for short-term trading, except for very skilled technical traders. The investment thesis hinges on the multi-quarter process of margin recovery, which requires patience. Given the extreme volatility, investors should be prepared for significant price swings and have a holding period long enough to allow the turnaround narrative to play out or fail.
